Compare Alcon AG (ALC) vs BlackBerry Limited (BB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs BlackBerry Limited — how do they compare? Alcon AG trades at $66.7 (market cap $32.69B), while BlackBerry Limited trades at $10.88 (market cap $6.49B). The key difference: Alcon AG is far larger — about 5× BlackBerry Limited's market cap, and Alcon AG pays a 0.54% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| ALC | BB | |
|---|---|---|
Market Cap | $32.69B | $6.49B |
Sector | Health | Technology |
52-Week High | $92.22 | $12.81 |
52-Week Low | $62.02 | $3.15 |
Enterprise Value | $36.28B | $6.36B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BlackBerry (BB) trades at $11.10, down 3.56% on the day but remains in a strong uptrend, having more than tripled year-to-date. The stock is technically bullish with recent earnings beats and improved guidance fueling optimism. Revenue growth is returning, with Q1 2026 results showing a profit turnaround, though valuation multiples remain elevated. Positive sentiment is driven by QNX software growth and the launch of leveraged ETFs tied to the stock.
Outlook is cautiously optimistic as execution on QNX and cybersecurity growth must justify high valuations. Key risks include competitive pressures and the need to sustain profitability. Analysts are mostly neutral with a consensus price target of $10.50, suggesting limited near-term upside from current levels amid rich pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →
